JOIN US FOR A MILESTONE, SCIENCE-TO-STRATEGY CME SUMMIT

Emerging Trends and Strategies in Thrombosis Medicine

Practical Dimensions of NOAC-Based Management

Acute and Extended Treatment of VENOUS THROMBOEMBOLISM

Focus on the Role of Factor Xa Inhibition for Acute and Extended Duration Treatment of PE and DVT

Principles of Practice at the Front Lines of Thrombosis Care

Practical Clinical and Cased-Based Approaches for Oral Factor Xa Inhibition Across the Spectrum of VTE Care

Save the Date: Wednesday, June 24, 2015 — CME Lunch Symposium


City: Toronto, Ontario | Location: Metro Toronto Convention Centre | Conference Room: Room 717, Level 700

REGISTER NOW: www.REG-ISTH.com

Funded by an independent educational grant from Bayer Healthcare

Jointly Sponsored by the University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC

This Satellite Program is not part of the official scientific program of the ISTH 2015 Congress
EDUCATIONAL AND LEARNING OBJECTIVES
Upon completion of the program, participants will be better able to:

• Manage acute and extended duration treatment of DVT and PE with non-monitored oral anticoagulants targeted at factor Xa;
• Describe the design, rationale, and results of clinical trials comparing injectable anticoagulants such as LMWH with oral agents targeting factor Xa; and, how to use factor Xa for acute treatment of PE and DVT;
• Risk-stratify patients with DVT and PE who are eligible for outpatient, oral-based therapy; and, optimize the benefit-risk equation for deploying factor Xa inhibition in VTE patients;
• Assess dosing requirements, based on renal function, of patients with DVT and PE, who are appropriate candidates for oral-based anticoagulation;
• Apply new ESC Guidelines for PE management to patients with acute PE;
• Understand how oral agents targeting factor Xa have the capacity to simultaneously treat both venous (blue) and arterial (red) states including VTE, ACS, and stroke prevention for AF;
• Transition patients from LMWH to an oral factor Xa inhibitor;
• Transition a patient with VTE who has been on a VKA to a factor Xa inhibitor.

TARGET AUDIENCE—WHO SHOULD ATTEND?
This complimentary CME educational activity is designed for all attendees of ISTH 2015 Congress.

DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint provid- ership of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCEM) and CMEducation Resources, LLC. The UMMS-OCEM is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The University of Massachusetts Medical School designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EDUCATIONAL SUPPORT
Supported by an educational grant from Bayer Healthcare